NCT05414500

Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides

Phase I Study of Mogamulizumab (M) in Combination With Brentuximab Vedotin (BV) in Previously Treated Cutaneous T Cell Lymphoma (CTCL) and Mycosis Fungoides (MF)

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 10 (estimated)
• Sponsor: University of Alabama at Birmingham · Academic / Other
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

This is an open label, single center, non-randomized dose de-escalation phase I study of combination of BV and Mogamulizumab. The primary objective of the study is to assess the safety and tolerability of the combination. The primary objective is also to explore safe dose of combination for future expansion.

Conditions

• Cutaneous T Cell Lymphoma
• Mycosis Fungoides

Interventions

Type	Name	Description
DRUG	Mogamulizumab	Administered IV
DRUG	Brentuximab vedotin	Administered IV

Timeline

• Start date: 2023-05-01
• Primary completion: 2026-04-30
• Completion: 2026-07-31
• First posted: 2022-06-10
• Last updated: 2026-04-09

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study